ArticleJournal of experimental & clinical cancer research : CR2025

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Lorenzo Castagnoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.